Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Best match
Most recent
precisionmedicineonline
9h
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd Benefit Despite Overall Survival Miss
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
precisionmedicineonline
9h
Astellas' Vyloy Approved in Europe as First-Line Treatment for CLDN18.2-Positive Gastric Cancer
The European Commission approval was based on two Phase III trials showing Vyloy plus chemo improved survival outcomes versus chemo alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Left note, bail denied
1951 kidnap victim found
Didn't authorize apology
1/3 think they have CTE
Asks to be put on NY ballot
Visits US ammunition plant
Friedkin set to buy Everton
Astronauts return to Earth
Robinson loses key staff
Economic speech this week
Closing last full-size store
Free COVID-19 tests
SpaceX plans Mars missions
No govt. shutdown for now
Dolphins legend Morris dies
Bulls escape MA rodeo
FBI: Violent crime declined
NE electoral change blocked
Reds fire manager
More troops to Middle East
NY reports death from EEE
Tech ban proposed
Gulf Coast storm warning
Makes new offer to union
Co-founder testifies
California sues ExxonMobil
Returning Indian antiquities
Colo. shooter found guilty
Makes emergency landing
Feedback